DDD Clinical Trial
Official title:
An Observational, Multi Center, Non-Randomized (Single Arm) Registration of the PerX360º System™
This is a multi-center, non-randomized post marketing surveillance registry including up to 125 patients treated with the PerX360º System™. Patients will receive a follow-up evaluation at the per physician defined time points: at discharge, an Interim 1 visit (1 month), an Interim 2 visit (3-6 months) and a Final visit (12 months). Imaging obtained at visits should be per standard of care.
For all patients participating in the registry, the following outcomes will be analyzed:
- Change in pain score on the Visual Analog Scale(VAS) from baseline for leg pain
- Change in pain score on the Visual Analog Scale(VAS) from baseline for back pain
- Change in Oswestry Disability Index (ODI) score from baseline
- Proportion of patients with a device related complication
- Proportion of patients with lack of revision, removal, or reoperation
- Proportion of patients with radiographic fusion
;
Observational Model: Case-Only
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05067127 -
Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
|
Phase 3 | |
Active, not recruiting |
NCT05809531 -
An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
|
Phase 3 | |
Completed |
NCT01343693 -
MaxAn Post Market Surveillance Validation
|
||
Available |
NCT04729062 -
C3G/Primary IC-MPGN EAP
|